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CyberKnife Stereotactic Radiosurgery is:
• the newest type of stereotactic radiosurgery; 
consisting of a 6-MV linear accelerator fixed on an 
image-guided, computer-operated frameless robotic 
arm
• 30 to 90 minutes per treatment 
• used to treat lungs, pancreas, brain, head and neck, 
spine and prostate cancers
• non-invasive and usually done in less than 5 
fractions (days) at a high dose, with a more minimal 
dose to surrounding tissue than conventional 
radiotherapy
• proven superior by its specialized target spatial 
localization system and steep dose gradient which 
allow for maximum sparing of organs at risk
• image-guided which allows the robotic arm to track 
patient movement within 0.5-10.0 mm and 1-3 
degrees and remain aligned to the target area
Treatment Process
• Retrotubular anesthesia is administered, achieving 
akinesis for 2.5-3 hours
• T2- and contrast-enhanced T1-weighted MRI is 
acquired (see Fig. 4)
• The doctor, dosimetrist and physicist spend 30-40 
minutes collaborating
• The visible tumor is contoured as the target volume
• Inverse treatment planning is done to create a steep 
fall in dose outside the tumor volume
• The patient is positioned on the table with an 
immobilization mask
• The linear accelerator delivers 100-150 beams at 
differing angles
• MR images are taken at each new angle to account 
for position of tumor due to movement
• The entire process is completed within 2.5 hours
Dose & Fractionation
• Treatments are non-isocentric
• Dose ranges on the size of the tumor and facility 
preference
• No standard recommendation for dose and 
fractionation exists (see examples below)
• 17-22 Gy in one fraction with 12/39 patient 
experiencing reoccurrence 
• 15 Gy over 3 fractions with partial regression 
after 12 months 
• 15 Gy over 3 fractions with complete recovery
• 19 patients treated with 24-35 Gy over 1-5 
fractions with 75% overall response rate
• 13 patients treated with 13-22 Gy over 3-5 
fractions with 100% overall response rate
Introduction
The purpose of the research done was to evaluate the use 
of CyberKnife Stereotactic Radiosurgery (SRS) for 
treating orbital lesions. Efficacy and tolerability of such 
treatment was analyzed with data drawn from multiple 
sources, regarding dose and fractionation, quality of life 
following treatment(s) and prognosis. CyberKnife SRS is 
the newest, most advanced model of radiation delivery 
systems, featuring a robotic arm capable of manipulating 
the linear accelerator into thousands of unique angles. 
The addition of new angles allows for a more precise 
concentration of radiation delivered to the lesions. In the 
case of optic lesions, it is crucial to minimize dose to 
adjacent structures such as optic nerve, lens and fovea. 
CyberKnife SRS is superior for treatment in small 
anatomical locations due to steep dose gradients and 
target localization system, allowing maximum sparing of 
organs at risk. While CyberKnife SRS is rapidly 
becoming the gold standard for orbital lesions, there is 
still a likelihood that other treatments may be required as 
an adjunct therapy for treatment purposes. However, 
current research identifies the high success rate of 
CyberKnife SRS but acknowledges the need for further 
research in dosage and fractionation. 
Conclusion
Most research points toward CyberKnife SRS as a 
safe, efficient and effective treatment method for 
orbital lesions. Currently, no recommendation exists 
about correct doses and fractionations for this 
treatment. These factors should be carefully planned 
according to proximity of critical structures, 
histology, and target lesion volume. Current research 
suggests CyberKnife is a safe and effective course of 
treatment. Further research must be conducted to 
fully understand the most efficient planning of 
treatment for orbital lesions using CyberKnife SRS.
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Prognosis/Outcome
• Primary lesion of the orbit 5-year survival rate: 85%
• Metastasized 5-year survival rate: 71%
• Most reported cases presented a monophasic 
disease course, yet there was some reoccurrence








• Reduced tumor volume (size), offering immediate 
symptom relief 
• Delays the need for surgery or enucleation
• Ideal for palliative treatment 
• Short treatment length allows focus on other 
procedures
Risks
• Orbital irradiation may lead to a wide spectrum of 
acute and late toxicities such as: permanent 
blindness, conjunctivitis, panophthalmitis, dry eye 
syndrome, cataract, keratopathy, retinopathy, 
neovascularization of the iris, and optic neuropathy
• Optic pathways and orbital adnexa are 
radiosensitive periocular structures that are prone to 
late toxicity
• In the long term, functional and cosmetic 
disturbances may reduce quality of life
Orbital Lesions
• Damage or abnormal change in tissue in or around 
the orbit
• Cancer that has metastasized to the eye is more 
common than a primary orbital cancer
• Melanoma is the most prevalent eye cancer, with 
uveal melanoma being the most frequent primary 
intraocular tumor
Types of Orbital Lesions
• Intraocular- within the orbit
• Periocular-surrounding the orbit (muscles & adnexa)
• Pseudotumor- swelling behind the orbit
• Primary or Metastasized
Etiology
• Age, thyroid disorders, systemic lupus erythematous, 
rheumatoid arthritis, fibro-inflammatory disorders, 
sarcoidosis, and granulomatosis with polyangiitis
• Mean age: 65 +/- 10
• Orbital metastases could usually be associated with a 
poor systemic prognosis
• Uveal melanoma is rare, but the most common 
cancer spread to the eye
Usually developed in the choroid, which has a 
similar function to skin cells
Signs/Symptoms
• Blurred or decreased vision
• Limited ocular motility







• Radiation Therapy treatment- CyberKnife, 
GammaKnife, IMRT, Proton therapy, 
Brachytherapy
• Enucleation or surgical resection 
• Systemic treatments- immunotherapy, hormonal 
therapy, chemotherapy
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